AAPL338.98+2.85 (+0.85%) ▲|ABBV264.48+0.52 (+0.20%) ▲|ABT102.98+0.37 (+0.36%) ▲|ACN186.11+4.82 (+2.66%) ▲|ADBE249.52+0.60 (+0.24%) ▲|AMAT464.24+19.67 (+4.42%) ▲|AMD615.52+55.70 (+9.95%) ▲|AMGN393.16+7.51 (+1.95%) ▲|AMT174.60+0.62 (+0.36%) ▲|AMZN258.45+4.74 (+1.87%) ▲|AVGO362.66+5.70 (+1.60%) ▲|AXP313.59+2.03 (+0.65%) ▲|BA201.15+2.95 (+1.49%) ▲|BAC57.96+0.23 (+0.40%) ▲|BKNG168.52+0.62 (+0.37%) ▲|BLK1,090.27+20.49 (+1.92%) ▲|BMY62.62-0.44 (-0.70%) ▼|BNY153.89+0.10 (+0.07%) ▲|BRK-B502.01-7.76 (-1.52%) ▼|C135.05+3.28 (+2.49%) ▲|CAT816.50+7.51 (+0.93%) ▲|CL86.26-1.21 (-1.38%) ▼|CMCSA22.93+0.19 (+0.84%) ▲|COF204.92+2.49 (+1.23%) ▲|COP127.53-4.30 (-3.26%) ▼|COST898.48+3.17 (+0.35%) ▲|CRM236.42-1.50 (-0.63%) ▼|CSCO111.46+1.95 (+1.78%) ▲|CVS87.60-1.24 (-1.40%) ▼|CVX203.67-5.84 (-2.79%) ▼|DE684.73+0.74 (+0.11%) ▲|DHR215.84+4.03 (+1.90%) ▲|DIS104.23+1.56 (+1.52%) ▲|DUK116.74-0.79 (-0.67%) ▼|EMR151.72+1.80 (+1.20%) ▲|FDX295.79-7.86 (-2.59%) ▼|GD353.90+0.85 (+0.24%) ▲|GE319.01+4.74 (+1.51%) ▲|GEV946.22+5.89 (+0.63%) ▲|GILD150.56+0.45 (+0.30%) ▲|GM83.95+1.75 (+2.13%) ▲|GOOG350.87+6.46 (+1.88%) ▲|GOOGL354.97+5.43 (+1.55%) ▲|GS959.39+17.39 (+1.85%) ▲|HD297.20-2.78 (-0.93%) ▼|HON206.48+0.02 (+0.01%) ▲|IBM231.93+2.38 (+1.04%) ▲|INTC121.78+13.18 (+12.14%) ▲|INTU304.12+0.93 (+0.31%) ▲|ISRG401.65+8.32 (+2.12%) ▲|JNJ269.47-0.52 (-0.19%) ▼|JPM352.04+2.37 (+0.68%) ▲|KO87.12-1.13 (-1.28%) ▼|LIN457.50-2.90 (-0.63%) ▼|LLY1,164.89+11.96 (+1.04%) ▲|LMT535.40+2.02 (+0.38%) ▲|LOW190.98-1.51 (-0.78%) ▼|LRCX302.28+14.17 (+4.92%) ▲|MA567.65+2.41 (+0.43%) ▲|MCD247.88-0.36 (-0.15%) ▼|MDLZ60.17-0.68 (-1.12%) ▼|MDT91.75-0.38 (-0.41%) ▼|META741.25+76.02 (+11.43%) ▲|MMM164.97-0.92 (-0.55%) ▼|MO68.53-0.99 (-1.42%) ▼|MRK149.50+2.63 (+1.79%) ▲|MS206.12+3.54 (+1.75%) ▲|MSFT501.61+7.83 (+1.59%) ▲|MU1,043.96+28.16 (+2.77%) ▲|NEE79.63-0.84 (-1.04%) ▼|NFLX73.36+1.57 (+2.19%) ▲|NKE36.10+0.59 (+1.66%) ▲|NOW137.68+2.21 (+1.63%) ▲|NVDA227.38+5.11 (+2.30%) ▲|ORCL148.56+0.95 (+0.64%) ▲|PEP129.59-0.16 (-0.12%) ▼|PFE27.74+0.08 (+0.29%) ▲|PG146.08-0.31 (-0.21%) ▼|PLTR183.09+5.45 (+3.07%) ▲|PM187.48-1.14 (-0.60%) ▼|QCOM194.23+16.51 (+9.29%) ▲|RTX194.34+0.34 (+0.18%) ▲|SBUX94.90-0.93 (-0.97%) ▼|SCHW106.88+1.63 (+1.55%) ▲|SO85.46-0.06 (-0.07%) ▼|SPG204.98-0.34 (-0.17%) ▼|T25.45+0.05 (+0.20%) ▲|TMO658.76+7.31 (+1.12%) ▲|TMUS165.27-2.91 (-1.73%) ▼|TSLA375.30+11.03 (+3.03%) ▲|TXN270.87+4.23 (+1.59%) ▲|UBER70.84+0.34 (+0.48%) ▲|UNH377.56+0.66 (+0.18%) ▲|UNP269.63-9.74 (-3.49%) ▼|UPS94.75-4.31 (-4.35%) ▼|USB60.44+0.38 (+0.63%) ▲|V369.95+1.66 (+0.45%) ▲|VZ47.68-0.41 (-0.85%) ▼|WFC86.54+0.42 (+0.49%) ▲|WMT107.44+0.71 (+0.67%) ▲|XOM158.30-5.24 (-3.20%) ▼|AAPL338.98+2.85 (+0.85%) ▲|ABBV264.48+0.52 (+0.20%) ▲|ABT102.98+0.37 (+0.36%) ▲|ACN186.11+4.82 (+2.66%) ▲|ADBE249.52+0.60 (+0.24%) ▲|AMAT464.24+19.67 (+4.42%) ▲|AMD615.52+55.70 (+9.95%) ▲|AMGN393.16+7.51 (+1.95%) ▲|AMT174.60+0.62 (+0.36%) ▲|AMZN258.45+4.74 (+1.87%) ▲|AVGO362.66+5.70 (+1.60%) ▲|AXP313.59+2.03 (+0.65%) ▲|BA201.15+2.95 (+1.49%) ▲|BAC57.96+0.23 (+0.40%) ▲|BKNG168.52+0.62 (+0.37%) ▲|BLK1,090.27+20.49 (+1.92%) ▲|BMY62.62-0.44 (-0.70%) ▼|BNY153.89+0.10 (+0.07%) ▲|BRK-B502.01-7.76 (-1.52%) ▼|C135.05+3.28 (+2.49%) ▲|CAT816.50+7.51 (+0.93%) ▲|CL86.26-1.21 (-1.38%) ▼|CMCSA22.93+0.19 (+0.84%) ▲|COF204.92+2.49 (+1.23%) ▲|COP127.53-4.30 (-3.26%) ▼|COST898.48+3.17 (+0.35%) ▲|CRM236.42-1.50 (-0.63%) ▼|CSCO111.46+1.95 (+1.78%) ▲|CVS87.60-1.24 (-1.40%) ▼|CVX203.67-5.84 (-2.79%) ▼|DE684.73+0.74 (+0.11%) ▲|DHR215.84+4.03 (+1.90%) ▲|DIS104.23+1.56 (+1.52%) ▲|DUK116.74-0.79 (-0.67%) ▼|EMR151.72+1.80 (+1.20%) ▲|FDX295.79-7.86 (-2.59%) ▼|GD353.90+0.85 (+0.24%) ▲|GE319.01+4.74 (+1.51%) ▲|GEV946.22+5.89 (+0.63%) ▲|GILD150.56+0.45 (+0.30%) ▲|GM83.95+1.75 (+2.13%) ▲|GOOG350.87+6.46 (+1.88%) ▲|GOOGL354.97+5.43 (+1.55%) ▲|GS959.39+17.39 (+1.85%) ▲|HD297.20-2.78 (-0.93%) ▼|HON206.48+0.02 (+0.01%) ▲|IBM231.93+2.38 (+1.04%) ▲|INTC121.78+13.18 (+12.14%) ▲|INTU304.12+0.93 (+0.31%) ▲|ISRG401.65+8.32 (+2.12%) ▲|JNJ269.47-0.52 (-0.19%) ▼|JPM352.04+2.37 (+0.68%) ▲|KO87.12-1.13 (-1.28%) ▼|LIN457.50-2.90 (-0.63%) ▼|LLY1,164.89+11.96 (+1.04%) ▲|LMT535.40+2.02 (+0.38%) ▲|LOW190.98-1.51 (-0.78%) ▼|LRCX302.28+14.17 (+4.92%) ▲|MA567.65+2.41 (+0.43%) ▲|MCD247.88-0.36 (-0.15%) ▼|MDLZ60.17-0.68 (-1.12%) ▼|MDT91.75-0.38 (-0.41%) ▼|META741.25+76.02 (+11.43%) ▲|MMM164.97-0.92 (-0.55%) ▼|MO68.53-0.99 (-1.42%) ▼|MRK149.50+2.63 (+1.79%) ▲|MS206.12+3.54 (+1.75%) ▲|MSFT501.61+7.83 (+1.59%) ▲|MU1,043.96+28.16 (+2.77%) ▲|NEE79.63-0.84 (-1.04%) ▼|NFLX73.36+1.57 (+2.19%) ▲|NKE36.10+0.59 (+1.66%) ▲|NOW137.68+2.21 (+1.63%) ▲|NVDA227.38+5.11 (+2.30%) ▲|ORCL148.56+0.95 (+0.64%) ▲|PEP129.59-0.16 (-0.12%) ▼|PFE27.74+0.08 (+0.29%) ▲|PG146.08-0.31 (-0.21%) ▼|PLTR183.09+5.45 (+3.07%) ▲|PM187.48-1.14 (-0.60%) ▼|QCOM194.23+16.51 (+9.29%) ▲|RTX194.34+0.34 (+0.18%) ▲|SBUX94.90-0.93 (-0.97%) ▼|SCHW106.88+1.63 (+1.55%) ▲|SO85.46-0.06 (-0.07%) ▼|SPG204.98-0.34 (-0.17%) ▼|T25.45+0.05 (+0.20%) ▲|TMO658.76+7.31 (+1.12%) ▲|TMUS165.27-2.91 (-1.73%) ▼|TSLA375.30+11.03 (+3.03%) ▲|TXN270.87+4.23 (+1.59%) ▲|UBER70.84+0.34 (+0.48%) ▲|UNH377.56+0.66 (+0.18%) ▲|UNP269.63-9.74 (-3.49%) ▼|UPS94.75-4.31 (-4.35%) ▼|USB60.44+0.38 (+0.63%) ▲|V369.95+1.66 (+0.45%) ▲|VZ47.68-0.41 (-0.85%) ▼|WFC86.54+0.42 (+0.49%) ▲|WMT107.44+0.71 (+0.67%) ▲|XOM158.30-5.24 (-3.20%) ▼|
16.5 C
New York
Tuesday, September 22, 2026

Tag: risk

newssourceFORcompanyinformationcontent1releasesmarket

MARITIME PARTNERS ANNOUNCES ZERO-EMISSION FERRY REFINANCING WITH SWITCH MARITIME

Financing Deal Paves Way for Upgraded Hydrogen-Powered Marine Technology NEW ORLEANS, June 24, 2025 /PRNewswire/ -- Maritime Partners, LLC ("Maritime Partners"), a leading provider of maritime...

DARZALEX® (daratumumab) reçoit le premier avis favorable du CHMP pour les patients atteints d’un myélome multiple indolent à haut risque

En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, offrant le potentiel de blocage de la progression de la maladie1

TELUS and TransUnion Launch Branded Call Display in Canada with Business Name, Logo and Call Reason

Solution helps businesses reach more customers, enhance engagement, and protect consumers from call spoofing and fraud            

Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab’s Phase 2b Trial (FORTIFY)

LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment...

Tims China Announces First Quarter 2025 Financial Results

System Sales Increased 3.5% Year-over-Year to RMB376.3 Million

Evaluating Annuities: Strategic Considerations for Retirement Planning

Annuities present themselves as appealing components of a retirement strategy, promising market-level returns without risk during accumulation, and guaranteed income during distribution. However, the...

Evaluating the Financial Risks of Importing Indian Mangoes to the U.S.

In the realm of global fruit trade, the importation of Indian mangoes into New Jersey presents a compelling case study of market dynamics, risk...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

FinVolution Announces Global AI Competition Targeting Deepfake Risks

SHANGHAI, June 24, 2025 /PRNewswire/ -- FinVolution Group has officially launched the 2025 FinVolution Global Data Science Competition today, with a spotlight on deepfake...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Krispy Kreme, Inc. (NASDAQ:DNUT), Strategy Incorporated (NASDAQ:MSTR), Organon & Co. (NYSE:OGN), and Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arvinas, Inc. (NASDAQ:ARVN), Semler Scientific Inc. (NASDAQ:SMLR), and Abacus Global Management, Inc. (NASDAQ:ABL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRisk

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers